HC Wainwright Trims IceCure Medical (NASDAQ:ICCM) Target Price to $2.50

IceCure Medical (NASDAQ:ICCM) had its target price cut by HC Wainwright from $3.00 to $2.50 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for IceCure Medical’s FY2024 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.25) EPS.

IceCure Medical Stock Up 4.6 %

Shares of IceCure Medical stock opened at $0.73 on Wednesday. The firm has a market cap of $33.15 million, a P/E ratio of -2.20 and a beta of 0.57. The business has a 50-day moving average price of $0.72 and a 200 day moving average price of $1.02. IceCure Medical has a fifty-two week low of $0.52 and a fifty-two week high of $1.57. The company has a quick ratio of 2.88, a current ratio of 3.39 and a debt-to-equity ratio of 0.03.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, August 20th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.90 million. IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. During the same period in the prior year, the company earned ($0.09) earnings per share. On average, sell-side analysts forecast that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC bought a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical at the end of the most recent quarter. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.